Insilico Medicine And SK Biopharmaceuticals Achieved AI-powered Drug Discovery Collaboration Worth Up to 2.5 Billion for Neuroimmune Disorders (IMAGE)

InSilico Medicine

Insilico Medicine And SK Biopharmaceuticals Achieved AI-powered Drug Discovery Collaboration Worth Up to 2.5 Billion for Neuroimmune Disorders

Caption

Under the agreement, Insilico will leverage its proprietary Pharma.AI platform, which spans target validation, generative chemistry, and molecule optimization, together with its preclinical drug discovery expertise to discover, design, and optimize novel candidates for neuroimmune indications. SK Biopharmaceuticals will contribute its extensive development and clinical capabilities in neuroimmune disorders, steering the late-stage development and commercialization of all resulting programs. Together, the two companies aim to accelerate discovery timelines and advance next-generation therapies for patients worldwide.

Credit

Insilico Medicine

Usage Restrictions

None

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.